Uni-Bio Group (HK690)'s Uni-PTH (Teriparatide) High-Precision Industrialization Project Was Successfully Approved Focus on the Transformation of Major Frontier Achievements Targeting the Tens of Billions Osteoporosis Market

April 18, 2019 9:25 AM

Uni-Bio Group (HK690)'s Uni-PTH (Teriparatide) High-Precision Industrialization Project Was Successfully Approved Focus on the Transformation of Major Frontier Achievements Targeting the Tens of Billions Osteoporosis Market HONG KONG / ACCESSWIRE / April 18, 2019 / A fully integrated biopharmaceutical company - Uni-Bio Science Group Limited ("Uni-Bio Science", together with its subsidiaries, referred to as the "Group"; Stock code: 0690.HK), is...

Read more

Avalon GloboCare to Host The 3rd Annual International Scientific Forum on Exosome Research and Application (ISFERA) in Beijing on July 19, 2019

April 17, 2019 8:00 AM

Co-organized with the Regenerative Medicine Foundation Concurrent with the 7th Annual Lu Daopei Hematology Forum FREEHOLD, NJ / ACCESSWIRE / April 17, 2019 / Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of innovative and transformative cell-based technologies and therapeutics, announced today that it will co-organize the 3rd Annual International Scientific Forum on Exosome Research and Application (ISFERA) with...

Read more

Vaso Corporation Announces Financial Results for Fourth Quarter and Full Year for 2018

April 15, 2019 9:00 AM

PLAINVIEW, NY / ACCESSWIRE / April 15, 2019 / Vaso Corporation ("Vaso") (OTC PINK: VASO) today reported its operating results for the three months and year ended December 31, 2018. "The Company's total revenue continued to increase, to $74.0 million, for the fiscal year 2018, thanks to the growth in our IT segment and proprietary medical equipment segment, at 3.9% and 12.7%, respectively," stated Dr. Jun Ma, President and Chief Executive Officer...

Read more

Dyadic Announces Uplisting to the Nasdaq Capital Market

April 15, 2019 8:00 AM

JUPITER, FL / ACCESSWIRE / April 15, 2019 / Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, is pleased to announce that its common stock has been approved to list on The Nasdaq Capital...

Read more

Lexaria Bioscience Engages Oak Hill Financial Inc. to Provide Investor Relations Services

April 15, 2019 6:00 AM

KELOWNA, BC / ACCESSWIRE / April 15, 2019 / Lexaria Bioscience Corp. (CNSX: LXX) (OTCQB: LXRP) ("Lexaria" or the "Company") announces it has retained Oak Hill Financial Inc. ("Oak Hill") to provide investor relations services to the Company in compliance with regulatory guidelines. Oak Hill is a Toronto-based firm that develops strategic platforms for its clients that are utilized to gain exposure and recognition in the capital markets. Oak...

Read more

HemaGenetics Announces Setting of the Effective Date for the Plan of Arrangement with 1169032 B.C. Ltd.

April 11, 2019 7:30 PM

VANCOUVER, BC / ACCESSWIRE / April 11, 2019 / HemaGenetics Technologies Corp. (the 'Company') is pleased to announce that further to the previously announced arrangement under the arrangement agreement entered into on June 26, 2018 between the Company, Mucho Cobre Resources Ltd. (formerly, 1169080 B.C. Ltd.), 1169029 B.C. Ltd., 1169032 B.C. Ltd., 1169071 B.C. Ltd., 1169077 B.C. Ltd., and 1169082 B.C. Ltd. (the 'Arrangement'), the...

Read more

Hancock Jaffe Successfully Completes Four VenoValve Implantations for First-in-Human Study

April 11, 2019 8:31 AM

Five Patients Now Part of First-in-Human Bogota Study IRVINE, CA / ACCESSWIRE / April 11, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ: HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, has successfully implanted VenoValves in four additional patients for its first-in-human study in Bogota, Colombia. The surgeries went well and there are no early signs of adverse events. HJLI previously announced that the...

Read more

EastWest Comments on 2Q Financial Statements and Expands on Vision, Strategy, and Execution

April 8, 2019 9:00 AM

VANCOUVER, BC / ACCESSWIRE / April 8, 2019 / EastWest Bioscience (the "Company" or "EastWest") (TSX.V: EAST) expands on its vision, strategy, and outlook for the future and comments on its 2Q financial results for the three months ended January 31, 2019. "It has been a very busy operational quarter," explains Rodney Gelineau, CEO of Eastwest BioScience. "The team has been tasked with integration of the Sangster's purchase, as well as...

Read more

Avalon GloboCare Appoints Finance Veteran Yue ''Charles'' Li to the Board of Directors

April 8, 2019 8:35 AM

Reappoints Meng Li to Board of Directors FREEHOLD, NJ / ACCESSWIRE / April 8, 2019 / Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of innovative and transformative cell-based technologies and therapeutics, announced today the addition of Yue "Charles" Li to the Company's Board of Directors. Mr. Li qualifies as an independent director and will serve on the acquisition task force committee. The Company also announced the...

Read more

Zivo Commences Third Dairy Cow Mastitis Trial to Validate Efficacy and Method of Administration for a New Pathogen Target

April 8, 2019 8:00 AM

KEEGO HARBOR, MI / ACCESSWIRE / April 8, 2019 / ZIVO Bioscience, Inc. (OTCQB: ZIVO) a Michigan-based biotech/agtech R&D company has commenced a third in vivo dairy cow mastitis study to validate its bioactive compounds in combating a specific infective pathogen via a specific method of administration. Neither the pathogen nor the method of administration can be disclosed at this time, other than to characterize the pathogen as a widespread...

Read more

AYOXXA Biosystems GmbH: AYOXXA launches LUNARIS(TM) Human and Mouse Chemokine Kits to explore chemokine signaling

April 8, 2019 5:25 AM

AYOXXA launches LUNARISTM Human and Mouse Chemokine Kits to explore chemokine signaling LUNARISTM Chemokine Kits are validated for the quantitative analysis of up to 12 different chemokines in one sample Panel composition is harmonized across species to allow translation of results from murine and human samples - from lab to clinic The LUNARISTM platform enables robust and scalable profiling of homeostatic and proinflammatory...

Read more

Brighthaven Ventures LLC Announces Dismissal of Lawsuit on Motion For Summary Judgement

April 5, 2019 8:45 AM

RESEARCH TRIANGLE PARK, NC / ACCESSWIRE / April 5, 2019 / Brighthaven Ventures LLC. ("BHV"), a wholly owned subsidiary of Avolynt, Inc., a company focused on the development of therapeutics for rare and metabolic diseases, announced today the dismissal of civil litigation against BHV executives in the United States District Court, Southern District of New York. In 2015, Richard Schoninger, Scott Schoninger, Jacqueline Schoninger, Gerald Allen,...

Read more

EBD Group: Vienna Welcomed 2,570 Life Science Executives for Partnering Success at BIO-Europe Spring(R) 2019

April 5, 2019 7:40 AM

ZUG, SWITZERLAND and VIENNA, AUSTRIA / ACCESSWIRE / April 5, 2019 / The highly successful thirteenth annual BIO-Europe Spring(R) international partnering conference wrapped up in Vienna, Austria, last week with a record 2,570 biotech, pharma and investment attendees who engaged in 15,428 one-to-one partnering meetings vying for over 3,600 licensing opportunities on offer. The event welcomed 1,465 companies overall. BIO-Europe Spring was produced...

Read more

HemaGenetics Technologies Announces Acquisition of HemaGenetic Research Group

April 4, 2019 3:20 PM

VANCOUVER, BC / ACCESSWIRE / April 4, 2019 / HemaGenetics Technologies Corp. (the "Company" or "HemaGenetics") announces that it has signed a Share Purchase and Sale Agreement (the "SPSA") to acquire the HemaGenetic Research Group ("HRG") owned and operated by Dr. Haixing Chen. The Company anticipates closing on the SPSA on or before Friday, April 12, 2019. About HRG HRG is a private research group that has developed patented gene technology for...

Read more

Pieris Pharmaceuticals to Present at the 2019 H.C. Wainwright Global Life Sciences Conference

April 3, 2019 8:50 AM

BOSTON, MA / ACCESSWIRE / April 3, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory, cancer and other diseases, announced today that Allan Reine, Senior Vice President and Chief Financial Officer of Pieris Pharmaceuticals, Inc. will present at the 2019 H.C. Wainwright Global Life Sciences Conference...

Read more

Vitro Biopharma Obtains CLIA Certification Complimenting its Ongoing Stem Cell Clinical Trials

April 2, 2019 9:30 AM

GOLDEN, CO / ACCESSWIRE / April 2, 2019 / Vitro Diagnostics, Inc. (OTC PINK: VODG), dba Vitro Biopharma announced receipt of a Certificate of Compliance with CLIA (Clinical Laboratory Improvement Amendment) without deficiencies. This allows Vitro Biopharma to perform clinical laboratory testing, reporting and billing in full compliance with the Clinical Laboratory Improvement Amendments of 1988 (CLIA) according to section 353 of the Public...

Read more

CBD-Infused Beverages Achieve Quality and Clarity Breakthrough Utilizing Pressure BioSciences' Ultra Shear Technology Platform

April 2, 2019 9:10 AM

New Video Demonstrates Revolution in Soft Drinks, Sports Drinks, and Beer with Vanishing Water-Soluble CBD Oil for Enhanced Quality and Absorption SOUTH EASTON, MA / ACCESSWIRE / April 2, 2019 / Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the life sciences and other industries, today...

Read more

Pieris Pharmaceuticals Presents Preclinical Data for GPC3/4-1BB Bispecific PRS-342 at the 2019 American Association for Cancer Research (AACR) Annual Meeting

April 2, 2019 8:00 AM

BOSTON, MA / ACCESSWIRE / April 2, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced the presentation of preclinical data for PRS-342, a GPC3/4-1BB immuno-oncology bispecific drug candidate, at a poster session at the 2019 American Association...

Read more

CORRECTION: GeneNews Announces Fourth Quarter 2018 Results and Year End Investor Call

April 2, 2019 7:30 AM

In the news release, "GeneNews Announces Fourth Quarter 2018 Results and Year End Investor Call", issued Friday, March 29, 2019 by GeneNews Limited over Accesswire, we are advised by the company that the date of the Conference Call has changed to Wednesday, April 3, 8:30 AM ET. The complete, corrected release follows: Conference Call - 8:30am, Wednesday April 3, 2019 TORONTO, ON / ACCESSWIRE / April 2, 2019 / GeneNews Limited ("GeneNews" or the...

Read more

Oncolytics Biotech (R) Presents Positive Clinical Biomarker Data at the American Association for Cancer Research Annual Meeting 2019

April 2, 2019 7:00 AM

- Clinical data highlight potential utility of T cell clonality as a predictive and prognostic biomarker of pelareorep therapy - - Using pelareorep in advance of the checkpoint inhibitor Keytruda® safely primes the immune system to target cancer cells in pancreatic cancer patients - CALGARY, AB and SAN DIEGO, CA / ACCESSWIRE / April 2, 2019 / Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an...

Read more